Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2024.109487 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Wee Han Ng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: qx21999@bristol.ac.uk. Hauptthemen laut MEDLINE: Liver Neoplasms, Colorectal Neoplasms, Microwaves, Radiofrequency Ablation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Radiofrequency Ablation (RFA) and Microwave Ablation (MWA) are alternative treatments for colorectal liver metastasis (CRLM) patients that are unsuitable for resection. However, consensus is lacking regarding selection criteria, tumour characteristics, ablation technique delivery, and device settings. This study aims to summarise current evidence to inform future prospective studies. METHODS: A systematic review was conducted following PRISMA guidelines. Studies assessing RFA and MWA treatment of CRLM were identified in Medline, Embase, Web of Science and the Cochrane database of systematic reviews, from inception until 31st August 2024. RESULTS: Fifty-two studies were included (retrospective cohort n = 45, prospective cohort n = 5, non-randomized comparative studies n = 2). Fifty-four inclusion criteria were used across 45 studies and were not stated in 7 studies. Tumours varied in mean number [1-8] and diameter (1.54-4.35 cm). Neoadjuvant chemotherapy use (10-100 % of patients), ablation delivery approach (open n = 4, laparoscopic n = 11, percutaneous n = 26, mixed n = 5), anaesthetic mode (GA n = 18, LA n = 11, mixed n = 2) and delivering clinician (radiologist n = 11, surgeon n = 16, both n = 1) all varied. Thirty-two studies lacked complete ablation device settings. Six studies followed a standardized ablation algorithm and 14 studies had specific settings. Five-year survival ranged from 0 to 69.7 % for ablation. CONCLUSIONS: There is significant heterogeneity in the reporting of study design, patient selection, and ablation techniques for CRLM. The lack of standardized approaches and inconsistent reporting of methodology and outcomes make it challenging to determine the optimal ablative treatment for CRLM. We recommend that future research should focus on clearly defining selection and treatment criteria, as well as treatment delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Bristol Medical School, University of Bristol, Bristol, UK. Electronic address: qx21999@bristol.ac.uk.
- Bristol Medical School, University of Bristol, Bristol, UK.
- Hepatobiliary Surgery Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- Bristol Medical School, University of Bristol, Bristol, UK; Department of Pancreatic and Hepatobiliary Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. Electronic address: jonathan.ree…
- Department of Pancreatic Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Zitieren
APA
Ng, W. H., Machado, C., Rooney, A., Jones, R., Rees, J., & Pathak, S. (2025). Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.109487
Vancouver
Ng WH, Machado C, Rooney A, Jones R, Rees J, Pathak S. Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2024.109487
BibTeX
@article{Ng2025,
author = {Ng, Wee Han and Machado, Catarina and Rooney, Alice and Jones, Robert and Rees, Jonathan and Pathak, Samir},
title = {Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2024.109487}
}
EUVIMED